Most-Upgraded StocksMost-UpgradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $819.09 +13.42 (+1.67%) Closing price 04:00 PM EasternExtended Trading$820.33 +1.24 (+0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get REGN alerts:Sign Up Key Stats Today's Range$800.00▼$825.5250-Day Range$726.47▼$852.0352-Week Range$572.75▼$859.34Volume852,262 shsAverage Volume692,734 shsMarket Capitalization$84.33 billionP/E Ratio20.68Dividend Yield0.46%Price Target$846.28Consensus RatingModerate Buy Company Overview Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders. Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst. Regeneron also maintains a pipeline of investigational therapies and has developed products through collaborations with companies including Sanofi and Bayer. Founded in 1988, Regeneron is headquartered in Tarrytown, New York. Its medicines are marketed in the United States and internationally, either directly or through commercial and development partnerships. The company serves patients and healthcare providers across multiple global markets. Regeneron was founded by Leonard S. Schleifer, who serves as president and chief executive officer, and George D. Yancopoulos, who serves as president and chief scientific officer. The company conducts research, manufacturing and commercial activities through operations in the United States and a global network of partners.AI Generated. May Contain Errors. Read More Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreREGN MarketRank™: 4.41456953642 of 5 starsRegeneron Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 44th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 22 buy ratings, 8 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Regeneron Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 23 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.35% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 8.35% in the coming year, from $48.87 to $52.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 20.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 20.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.88.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the float of Regeneron Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 14.89%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRegeneron Pharmaceuticals has a dividend yield of 0.48%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Regeneron Pharmaceuticals is 9.29%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 7.10% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.Read more about Regeneron Pharmaceuticals' dividend. News and Social Media3.7 / 5News Sentiment0.88 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Regeneron Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 10 people have searched for REGN on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows14 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,506,845.00 in company stock.Percentage Held by Insiders6.97% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Stock News HeadlinesRegeneron: Is The Market Undervaluing Its Growth PotentialOctober 22 at 10:00 AM | seekingalpha.comRegeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Piper Sandler Analyst SaysOctober 21 at 1:42 AM | americanbankingnews.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 22 at 1:00 AM | Weiss Ratings (Ad)Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial ResultsOctober 19 at 5:27 PM | finance.yahoo.comStrong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial ResultsOctober 19 at 2:51 PM | insidermonkey.comForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketOctober 19 at 10:24 AM | fool.comRegeneron's Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)October 19 at 4:04 AM | americanbankingnews.comForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit ShareOctober 17, 2026 | fool.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $771.87 at the start of the year. Since then, REGN stock has increased by 6.1% and is now trading at $819.09. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. The business's quarterly revenue was up 16.7% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include these companies: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional shareholders include Robeco Institutional Asset Management B.V. (0.39%), Pinnacle Associates Ltd. (0.08%), Vest Financial LLC (0.07%) and Atwood & Palmer Inc. (0.04%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Andrew J Murphy, Joseph J Larosa, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Christine A Poon, Bonnie L Bassler, Huda Y Zoghbi, Michael S Brown and Kathryn Guarini. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Micron Technology (MU), Alibaba Group (BABA) and Gilead Sciences (GILD). Company Calendar Last Earnings7/30/2026Record date for 8/31 Dividend8/18/2026Ex-Dividend for 8/31 Dividend8/18/2026Dividend Payable8/31/2026Today10/22/2026Next Earnings (Estimated)10/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, REGN's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees15,410Year Founded1988Price Target and Rating Average Price Target for Regeneron Pharmaceuticals$846.28 High Price Target$1,030.00 Low Price Target$185.00 Potential Upside/Downside+3.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage31 Analysts Profitability EPS (Trailing Twelve Months)$40.46 Trailing P/E Ratio20.68 Forward P/E Ratio16.76 P/E Growth1.37Net Income$4.50 billion Net Margins27.86% Pretax Margin33.26% Return on Equity13.47% Return on Assets10.34% Debt Debt-to-Equity Ratio0.06 Current Ratio3.34 Quick Ratio2.78 Sales & Book Value Annual Sales$14.34 billion Price / Sales5.88 Cash Flow$42.68 per share Price / Cash Flow19.19 Book Value$295.66 per share Price / Book2.77Miscellaneous Outstanding Shares102,960,000Free Float95,779,000Market Cap$84.33 billion OptionableOptionable Beta0.16 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:REGN) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
